Effects of LTD4 on Human Airway Smooth Muscle Cell Proliferation, Matrix Expression, and Contraction In Vitro: Differential Sensitivity to Cysteinyl Leukotriene Receptor Antagonists
- 1 September 1998
- journal article
- Published by American Thoracic Society in American Journal of Respiratory Cell and Molecular Biology
- Vol. 19 (3) , 453-461
- https://doi.org/10.1165/ajrcmb.19.3.2999
Abstract
The cysteinyl leukotrienes (CysLTs) mimic many of the features of asthma and are implicated in its pathophysiology. Little, however, is known about the effects of the CysLTs on airways remodeling. In this study the effects of leukotriene D4 (LTD4) on human airway smooth muscle (HASM) cell proliferation and expression of extracellular matrix proteins were investigated. LTD4 (0.1-10 microM) alone had no effect on DNA synthesis in HASM. LTD4, however, markedly augmented proliferation induced by the mitogen, epidermal growth factor (EGF, 1 ng/ml). The potentiating effect of LTD4 (1 microM) on EGF-induced DNA synthesis was abolished by pranlukast (1 microM) or pobilukast (30 microM), but unaffected by zafirlukast (1 microM). In contrast, pranlukast (pKB = 6.9), pobilukast (pKB = 7.0), and zafirlukast (pKB = 6.5) had equivalent potencies for inhibition of LTD4-induced contraction in human bronchus. LTD4 (0.1 or 10 microM) did not increase the total messenger RNA expression of the extracellular matrix proteins (pro-alpha[I] type I or alpha1[IV] type IV collagen), elastin, biglycan, decorin, and fibronectin, and did not influence tumor growth factor-beta (10 ng/ml)-induced effects on the expression of these proteins in HASM cells. These data indicate that LTD4 augments growth factor-induced HASM proliferation but does not alter the expression of various extracellular matrix components. The observed differences in sensitivity to the antagonists suggests that the former phenomenon may be mediated by a CysLT receptor distinct from that which mediates LTD4-induced HASM contraction. Collectively, these results provide preliminary evidence that CysLTs may play a role in airways remodeling in asthma.Keywords
This publication has 32 references indexed in Scilit:
- Leukotriene receptorsJournal of Lipid Mediators and Cell Signalling, 1995
- Cysteinyl leukotrienes in asthma: old mediators up to new tricksTrends in Pharmacological Sciences, 1995
- Effect of a new leukotriene receptor antagonist, ONO-1078, on human bronchial smooth muscle in vitroProstaglandins, Leukotrienes & Essential Fatty Acids, 1993
- In Vitro Antagonism of ONO-1078, a Newly Developed Anti-Asthma Agent, against Peptide Leukotrienes in Isolated Guinea Pig Tissues.The Japanese Journal of Pharmacology, 1992
- Differential effect of transforming growth factor β on proteoglycan synthesis in human embryonic lung fibroblastsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1991
- The Preclinical and Clinical Pharmacology of SK&F 104353, a Potent and Selective Peptidoleukotriene Receptor AntagonistAnnals of the New York Academy of Sciences, 1991
- Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjectsThe Lancet, 1991
- Modulation of procollagen gene expression by retinoids. Inhibition of collagen production by retinoic acid accompanied by reduced type I procollagen messenger ribonucleic acid levels in human skin fibroblast cultures.Journal of Clinical Investigation, 1985
- Human cellular fibronectin: comparison of the carboxyl-terminal portion with rat identifies primary structural domains separated by hypervariable regionsBiochemistry, 1985
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979